id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-5681-0006,FDA,FDA-2024-E-5681,"Determination of Regulatory Review Period for Purposes of Patent Extension; ALTIUS DIRECT ELECTRICAL NERVE STIMULATION
SYSTEM",Notice,Determinations,2025-11-24T05:00:00Z,2025,11,2025-11-24T05:00:00Z,2026-05-27T03:59:59Z,2025-11-24T19:32:14Z,2025-20668,1,0,09000064b9093521
FDA-2024-E-5681-0005,FDA,FDA-2024-E-5681,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-08-27T04:00:00Z,2025,8,2025-08-27T04:00:00Z,,2025-08-27T21:59:37Z,,0,0,09000064b8f19b20
FDA-2024-E-5681-0004,FDA,FDA-2024-E-5681,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-06-17T04:00:00Z,2025,6,2025-06-17T04:00:00Z,,2025-06-18T00:38:34Z,,0,0,09000064b8e16a15
FDA-2024-E-5681-0003,FDA,FDA-2024-E-5681,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-03-18T04:00:00Z,2025,3,2025-03-18T04:00:00Z,,2025-03-18T15:04:20Z,,0,0,0900006486a02db7
FDA-2024-E-5681-0002,FDA,FDA-2024-E-5681,"Patent Extension Application from Shay Glenn LLP (on behalf of Neuros Medical, Inc.)",Other,Application,2024-12-10T05:00:00Z,2024,12,2024-12-10T05:00:00Z,,2024-12-10T15:07:26Z,,0,0,090000648685aa49
FDA-2024-E-5681-0001,FDA,FDA-2024-E-5681,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-12-10T05:00:00Z,2024,12,2024-12-10T05:00:00Z,,2024-12-10T15:06:15Z,,0,0,090000648685aa48